McKenna Mark C. 4

What Happened Mark C. McKenna, a director of Apogee Therapeutics, was granted a derivative award on 2026-06-09 giving him the right to purchase 7,657 shares of Apogee common stock. The reported grant shows a $0.00 per-share acquisition price on the Form 4; the footnote clarifies this instrument is an option that will vest on the one-year anniversary of the grant subject to continued service. This was a grant (award) — not an immediate purchase or sale.

Key Details

• Transaction date: 2026-06-09; Form 4 filed 2026-06-11 (appears timely).
• Instrument: Option/derivative to purchase 7,657 shares; reported acquisition price $0.00.
• Vesting: Option vests on the one-year anniversary of the grant, subject to continued service (see footnote F1).
• Shares owned after transaction: Not disclosed in the provided filing data.
• Transaction code: A = Award/Grant (derivative); no sale or exercise reported.

Context This grant is a typical director equity award that vests over time; it does not represent an immediate cash outlay or sale of shares. Because it’s a derivative award that must vest before it can be exercised/converted into shares, it does not by itself indicate buying or selling activity by the insider.